Fig. 5.

Tumour cell-reactive antibodies can be detected in the supernatants of IL-17+BAFF+CpG-stimulated B cells form melanoma patients. (A) A representative screen for tumour cell-reactive antibodies secreted after 10 days in supernatants of B-cell cultures from one of three patients with melanoma (Table 1 shows summary of data from three patients). Tumour cell-reactive antibodies were compared to a Negative control (non-specific human IgG, red bar) and a positive control (black bar, trastuzumab IgG, recognizing HER2/neu-expressing A375 cells) in the cell-based ELISA. Each blue bar represents a supernatant sample from one B-cell culture well. Samples showing specific binding to A375 melanoma cells (OD values > 75% of the positive IgG control) were considered reactive.